Unique ID issued by UMIN | UMIN000018170 |
---|---|
Receipt number | R000021047 |
Scientific Title | Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients |
Date of disclosure of the study information | 2015/07/06 |
Last modified on | 2016/11/27 10:36:32 |
Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients
Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients
Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients
Comparison of satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors in type 2 diabetic patients
Japan |
type 2 diabetes
Endocrinology and Metabolism |
Others
NO
To compare patients' satisfaction and adherence among once-daily, twice-daily, and once-weekly DPP-4 inhibitors
Efficacy
Patients' satisfaction
Adherence
Blood glucose
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Active
6
Treatment
Medicine |
Treated with trelagliptin (once weekly) in period 1, teneligliptin (once daily) in period 2, and vildagliptin (twice daily) in period 3.
Treated with trelagliptin (once weekly) in period 1, vildagliptin (twice daily) in period 2, and teneligliptin (once daily) in period 3.
Treated with teneligliptin (once daily) in period 1, trelagliptin (once weekly) in period 2, and vildagliptin (twice daily) in period 3.
Treated with teneligliptin (once daily) in period 1, vildagliptin (twice daily) in period 2, and trelagliptin (once weekly) in period 3.
Treated with vildagliptin (twice daily) in period 1, teneligliptin (once daily) in period 2, and trelagliptin (once weekly) in period 3.
Treated with vildagliptin (twice daily) in period 1, trelagliptin (once weekly) in period 2, and teneligliptin (once daily) in period 3.
20 | years-old | <= |
Not applicable |
Male and Female
Type 2 diabetic patients treated with alogliptin
- Patients with severe hepatic, renal, and/or cardiac disease
- Patients with hypersentitivity to the agents used in the current study
- Patients who are pregnant, breast-feeding or may become pregnant
- Patients who are judged by the investigator to be inappropriate for this study for any other reason.
180
1st name | |
Middle name | |
Last name | Toshihiko Shiraiwa |
Shiraiwa Medical Clinic
Shiraiwa Medical Clinic
4-10-24 Hozenji, Kashiwara, Osaka 582-0005, Japan
072-971-1221
shiraiwa@endmet.med.osaka-u.ac.jp
1st name | |
Middle name | |
Last name | Toshihiko Shiraiwa |
Shiraiwa Medical Clinic
Shiraiwa Medical Clinic
4-10-24 Hozenji, Kashiwara, Osaka 582-0005, Japan
072-971-1221
shiraiwa@endmet.med.osaka-u.ac.jp
Shiraiwa Medical Clinic
Shiraiwa Medical Clinic
Self funding
Smile Pharmacy
NO
2015 | Year | 07 | Month | 06 | Day |
Unpublished
Terminated
2015 | Year | 07 | Month | 04 | Day |
2015 | Year | 07 | Month | 06 | Day |
2015 | Year | 07 | Month | 02 | Day |
2016 | Year | 11 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021047
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |